Forum for Science, Industry and Business
Sponsored by:     Siemens  n-tv 
Search our Site:

Topic (optional):

 

Home Reports Health and Medicine Content

Joint Project to Develop a Revolutionary Drug Discovery Product.

next article
23.08.2004

 


InterBioScreen (IBS), global provider of unique chemical compound libraries, and Quantum Pharmaceuticals, high-tech drug discovery company, announced a new project to create a revolutionary product for the drug discovery market.

The joint project, QuantumLead, combines the industry leading in silico lead optimization technology of Quantum Pharmaceuticals with the unique synthetic and natural compound libraries and network of scientists of IBS to create Q-Lead-Libraries.


Q-Lead-Libraries are libraries of compounds, which are ranked according to their constant affinity to particular protein targets. They are designed to allow biotech and pharmaceutical companies to achieve a dramatic acceleration of the drug discovery R&D process by reducing or eliminating the time involved in screening and optimization of hits and leads. Using Q-Lead Libraries will enable biotech and pharmaceuticals companies to find exclusive novel drug candidates more quickly and at a lower cost.

The technology behind Q-Lead-Libraries™ is Quantum Pharmaceuticals’ proprietary intermolecular modeling tools and accurate affinity calculations. The technology provides for full flexibility of both ligands and proteins and takes into account all factors of binding free energy including solvation effects, Van Der Waals energy in solution, as well as electrostatic and entropy contribution.

The joint in-house drug development program is expected to produce a broad range of novel drug candidates for HIV-1 integrase (AIDS), hsp90 (oncology) and beta-secretase (Alzheimer’s Disease) that will be marketed and out-licensed by both companies at the preclinical stage.

About Quantum Pharmaceuticals: Quantum Pharmaceuticals is a Moscow-based biotech company, which has created and continues to develop computational drug discovery technology that is breaking the limits of computational simulation of molecular interactions.

About InterBioScreen: InterBioScreen is one of the largest global providers of high quality chemical libraries for pharmaceutical, biotech and agricultural companies. InterBioScreen carries out targeted synthesis of new chemical drug-like compounds which cannot be synthesized by combinatorial methods, including new and unusual classes of organic compounds.

Courtney Ranson | Source: Quantum Pharmaceuticals
Further information: www.q-pharm.com
www.ibscreen.com

next article

More articles from Health and Medicine:

nachricht Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
24.11.2009 | Johns Hopkins Medical Institutions

nachricht Moderate-to-Heavy Exercise May Reduce Risk of Stroke for Men
24.11.2009 | American Academy of Neurology

All articles from Health and Medicine >>>

B2B Search

Product / Service
Company / Organisation

Latest News

Daycare may double TV time for young children

24.11.2009 | Studies and Analyses

Insomnia prevalent among cancer patients who receive chemotherapy

24.11.2009 | Studies and Analyses

How green is your house?

24.11.2009 | Social Sciences

VideoLinks

Event News

Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients

20.11.2009 | Event News

'Golden Age' for clinical psychology in Northern Ireland

20.11.2009 | Event News

New Perspectives in Marine Anti-Fouling Research

11.11.2009 | Event News